Published in BMC Cancer on January 18, 2013
Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis. BMC Cancer (2016) 0.83
Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy. BMC Cancer (2016) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst (2008) 8.70
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol (2006) 5.86
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol (2006) 4.66
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer (2007) 3.98
Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol (2009) 3.70
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer (2007) 2.75
Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer (2004) 2.59
Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer (2001) 2.35
Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res (2005) 2.32
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2009) 2.26
Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res (2002) 2.20
HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol (2008) 1.99
Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol (2010) 1.94
Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer (1993) 1.86
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res (2002) 1.57
Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. Eur J Cancer (2010) 1.15
Presence of HPV in head and neck tumours: high prevalence in tonsillar localization. J Exp Clin Cancer Res (2004) 1.01
Human papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: roles of p53 and caspase activation. J Cell Biochem (2000) 0.95
NFI-Ski interactions mediate transforming growth factor beta modulation of human papillomavirus type 16 early gene expression. J Virol (2004) 0.94
p53: biology and role for cellular radiosensitivity. Strahlenther Onkol (2000) 0.92
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst (2008) 3.60
Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med (2010) 2.99
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics (2012) 2.01
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 1.59
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res (2008) 1.55
Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist (2009) 1.53
[Epidemiological study of the GEICAM group about breast cancer in Spain (1990-1993): El Alamo project]. Med Clin (Barc) (2004) 1.41
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat (2010) 1.22
New cutaneous toxicities with generic docetaxel: are the excipients guilty? Support Care Cancer (2014) 1.14
Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol (2008) 1.08
18F-FDG-PET/CT in predicting pathologic complete response after neoadjuvant chemotherapy: the early metabolic response is the answer. Eur J Cancer (2013) 1.06
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays (2007) 1.05
Missing data imputation using statistical and machine learning methods in a real breast cancer problem. Artif Intell Med (2010) 1.04
Maintenance treatment in metastatic breast cancer. Expert Rev Anticancer Ther (2008) 1.04
Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res (2013) 1.00
Neuronal selectivity, population sparseness, and ergodicity in the inferior temporal visual cortex. Biol Cybern (2007) 1.00
Clustering of DNA words and biological function: a proof of principle. J Theor Biol (2011) 0.98
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. Breast Cancer Res Treat (2010) 0.97
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res (2014) 0.95
Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers. Eur J Cancer Prev (2013) 0.94
Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer. Am J Clin Pathol (2006) 0.94
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer (2010) 0.93
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res (2013) 0.93
Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. Oral Oncol (2012) 0.92
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology (2010) 0.92
The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer. Cancer Treat Rev (2013) 0.89
Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Res Treat (2006) 0.88
Detection methods predict differences in biology and survival in breast cancer patients. BMC Cancer (2012) 0.87
The functional interaction of 14-3-3 proteins with the ERK1/2 scaffold KSR1 occurs in an isoform-specific manner. J Biol Chem (2008) 0.87
Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha. BMC Cancer (2008) 0.87
Behavioural and neurochemical effects of combined MDMA and THC administration in mice. Psychopharmacology (Berl) (2007) 0.87
Clusterin expression is associated with decreased disease-free survival of patients with colorectal carcinomas. Histopathology (2010) 0.86
A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol (2006) 0.85
Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. Clin Transl Oncol (2011) 0.85
Functions and workload of medical oncologists in Spain. Clin Transl Oncol (2012) 0.85
Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin. Clin Transl Oncol (2012) 0.83
Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer. Oncology (2009) 0.83
Application of genetic algorithms and constructive neural networks for the analysis of microarray cancer data. Theor Biol Med Model (2014) 0.83
Multimodal treatment of desmoid tumours: the significance of local control. Clin Transl Oncol (2011) 0.83
Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. PLoS One (2009) 0.82
Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients. Cancer Biomark (2007) 0.82
Outcome of small invasive breast cancer with no axillary lymph node involvement. Breast J (2010) 0.82
Male breast cancer: immunohistochemical subtypes and clinical outcome characterization. Oncology (2012) 0.82
Regulation of clusterin expression in human cancer via DNA methylation. Tumour Biol (2009) 0.81
Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. Pharmacogenet Genomics (2014) 0.80
Serum protein levels following surgery in breast cancer patients: a protein microarray approach. Int J Oncol (2012) 0.80
SEOM clinical guidelines: a necessary tool. Clin Transl Oncol (2011) 0.80
Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol (2009) 0.80
Efficient Implementation of the Backpropagation Algorithm in FPGAs and Microcontrollers. IEEE Trans Neural Netw Learn Syst (2015) 0.80
Pattern of expression of CXCR4 and adhesion molecules by human CD34+ cells from different sources: role in homing efficiency in NOD/SCID mice. Haematologica (2004) 0.79
Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment. Clin Lymphoma Myeloma (2006) 0.79
Prognosis of microinvasive breast carcinoma with negative axillary nodes in accordance with TNM classification criteria. Breast J (2010) 0.79
Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain? Clin Transl Oncol (2012) 0.79
The role and prognostic value of apoptosis in colorectal carcinoma. BMC Clin Pathol (2013) 0.79
SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs). Clin Transl Oncol (2012) 0.78
Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss? Med Hypotheses (2013) 0.78
Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. Leuk Lymphoma (2011) 0.78
Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question? Clin Transl Oncol (2010) 0.78
Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation. Head Neck (2010) 0.78
Role of vascular endothelial growth factor C in classical Hodgkin lymphoma. Leuk Lymphoma (2015) 0.78
Informed prognosis [corrected] after abdominal aortic aneurysm repair using predictive modeling techniques [corrected]. J Vasc Surg (2006) 0.77
Presentation of Hodgkin's lymphoma with Ophelia syndrome. J Clin Oncol (2007) 0.77
Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clin Transl Oncol (2012) 0.77
Information in the first spike, the order of spikes, and the number of spikes provided by neurons in the inferior temporal visual cortex. Vision Res (2006) 0.77
Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer. Breast Cancer Res Treat (2010) 0.76
A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. Cancer Chemother Pharmacol (2003) 0.76
Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain. Med Clin (Barc) (2008) 0.76
Prognostic value of serum angiogenic activity in colorectal cancer patients. J Cell Mol Med (2007) 0.76
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study. Eur J Cancer (2005) 0.76
Collet-Sicard syndrome as an initial presentation of prostate cancer: a case report. J Med Case Rep (2011) 0.76
Relationship between plasma levels of soluble CD40L and insulin sensitivity and insulin secretion status in non-diabetic dyslipidemic patients. Diabetes Res Clin Pract (2007) 0.76
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. Oncologist (2016) 0.76
Update on the diagnosis of cancer of unknown primary (CUP) origin. Clin Transl Oncol (2011) 0.76
Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission. Clin Lymphoma Myeloma (2007) 0.75
Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice. J Clin Oncol (2009) 0.75
Adjuvant high-dose interferon therapy for melanoma: nothing has really changed. Melanoma Res (2014) 0.75
Effects of various cannabinoid ligands on choice behaviour in a rat model of gambling. Behav Pharmacol (2016) 0.75
Looking for the right drug for the right patient: a tale of old drugs and new pathways. Clin Transl Oncol (2005) 0.75
Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group. Clin Breast Cancer (2003) 0.75
Mantle cell lymphoma stage IV affecting lacrimal glands, retro-orbital tissue, optic nerve and ocular motor muscles. Clin Transl Oncol (2009) 0.75
[Autosomal dominant punctate palmoplantar keratoderma]. Actas Dermosifiliogr (2006) 0.75
Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens. Anticancer Drugs (2013) 0.75
An uncommon presentation of non-Hodgkin's lymphoma: diffuse large-cell lymphoma presenting as a peritoneal mass. Leuk Lymphoma (2006) 0.75
Practical guidelines for dose individualization of anticancer targeted drugs. Clin Transl Oncol (2012) 0.75
Targeted therapies in the treatment of germ cell tumors: the need for new approaches against "orphan" tumors. Crit Rev Oncol Hematol (2012) 0.75
Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. Clin Transl Oncol (2008) 0.75
Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. Clin Transl Oncol (2012) 0.75
Time-to-progression in breast cancer: a stratification model for clinical trials. Breast (2007) 0.75
Courses on mechanical ventilation in pediatrics: first experience in Spain. Pediatr Pulmonol (2007) 0.75